NasdaqCM - Nasdaq Real Time Price USD

Citius Pharmaceuticals, Inc. (CTXR)

0.7500
+0.0510
+(7.30%)
At close: May 9 at 4:00:01 PM EDT
0.7227
-0.03
(-3.64%)
After hours: May 9 at 7:50:02 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
9/30/2024
9/30/2023
9/30/2022
9/30/2021
Total Revenue
0
0
0
0
0
Operating Expense
42,694.4720
41,995.6810
36,732.0180
33,316.0450
23,531.8940
Operating Income
-42,694.4720
-41,995.6810
-36,732.0180
-33,316.0450
-23,531.8940
Net Non Operating Interest Income Expense
526.9700
758
1,179.4170
251.3990
250.9860
Other Income Expense
110.2070
2,387.8420
3,585.6890
--
226.4740
Pretax Income
-39,779.6600
-38,849.8390
-31,966.9120
-33,064.6460
-23,054.4340
Tax Provision
696.2400
576
576
576
0
Net Income Common Stockholders
-40,723.2120
-40,186.1510
-33,694.1200
-33,640.6460
-24,505.3100
Diluted NI Available to Com Stockholders
-40,723.2120
-40,186.1510
-33,694.1200
-33,640.6460
-24,505.3100
Basic EPS
-5.82
-5.97
-5.57
-5.75
-5.75
Diluted EPS
-5.82
-5.97
-5.57
-5.75
-5.75
Basic Average Shares
7,010.5550
6,726.9990
6,051.7890
5,843.2950
4,343.9630
Diluted Average Shares
7,010.5550
6,726.9990
6,051.7890
5,843.2950
4,343.9630
Total Operating Income as Reported
-42,694.4720
-41,995.6810
-36,732.0180
-33,316.0450
-23,531.8940
Total Expenses
42,694.4720
41,995.6810
36,732.0180
33,316.0450
23,531.8940
Net Income from Continuing & Discontinued Operation
-39,675.9000
-39,138.8390
-32,542.9120
-33,640.6460
-23,054.4340
Normalized Income
-39,675.9000
-39,138.8390
-32,542.9120
-33,640.6460
-23,220.9910
Interest Income
526.9700
758
1,179.4170
251.3990
261.8250
Interest Expense
--
--
--
0
10.8390
Net Interest Income
526.9700
758
1,179.4170
251.3990
250.9860
EBIT
-42,694.4720
-41,995.6810
-36,732.0180
-33,316.0450
-23,043.5950
EBITDA
-42,481.0340
-41,786.0700
-36,537.7020
-33,136.3680
-22,878.7270
Reconciled Depreciation
213.4380
209.6110
194.3160
179.6770
164.8680
Net Income from Continuing Operation Net Minority Interest
-39,675.9000
-39,138.8390
-32,542.9120
-33,640.6460
-23,054.4340
Total Unusual Items Excluding Goodwill
--
--
--
0
166.5570
Total Unusual Items
--
--
--
0
166.5570
Normalized EBITDA
-42,481.0340
-41,786.0700
-36,537.7020
-33,136.3680
-23,045.2840
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0002
0
Tax Effect of Unusual Items
0
0
0
0
0
9/30/2021 - 10/2/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ATNM Actinium Pharmaceuticals, Inc.
1.4800
+3.50%
 
HOTH Hoth Therapeutics, Inc.
0.9526
-1.69%
 
CMPX Compass Therapeutics, Inc.
1.8200
+2.25%
 
CVM CEL-SCI Corporation
0.2468
-3.14%
 
ABEO Abeona Therapeutics Inc.
5.27
-4.01%
 
STRO Sutro Biopharma, Inc.
0.8715
-9.06%
 
GNPX Genprex, Inc.
0.2853
-0.56%
 
APVO Aptevo Therapeutics Inc.
0.3400
-5.56%
 
AUTL Autolus Therapeutics plc
1.3200
-2.22%
 
MAIA MAIA Biotechnology, Inc.
2.0400
+4.08%